Tsung-Wen Chen
Overview
Explore the profile of Tsung-Wen Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
284
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yeh C, Chen M, Chang Y, Wu R, Tsao L, Wang S, et al.
Mol Carcinog
. 2018 Oct;
58(2):270-278.
PMID: 30334579
Cholangiocarcinoma (CCA) is a devastating disease with very poor prognosis due to late diagnosis and resistance to traditional chemotherapies and radiotherapies. Herein, thioacetamide (TAA)-induced rat CCA model and CGCCA cell...
2.
Chang C, Yeh C, Chung Y, Chen Y, Tien S, Chen T, et al.
Drug Des Devel Ther
. 2018 Jun;
12:1467-1478.
PMID: 29872269
Background: An F-tagged NSAID analog was prepared for use as a probe for COX-2 expression, which is associated with tumor development. Methods: The in vivo uptake of celecoxib was monitored...
3.
Yeh C, Chang C, Chung Y, Tien S, Chen Y, Chen T, et al.
Data Brief
. 2017 Oct;
15:174-202.
PMID: 29021997
The data presented in this article are related to the research article entitled "Synthesis and Characterization of Boron Fenbufen and its F-18 Labeled Homolog for Boron Neutron Capture Therapy of...
4.
Yeh C, Chang C, Chung Y, Tien S, Chen Y, Chen T, et al.
Eur J Pharm Sci
. 2017 Jul;
107:217-229.
PMID: 28728977
Boron neutron capture therapy (BNCT) is a binary therapy that employs neutron irradiation on the boron agents to release high-energy helium and alpha particles to kill cancer cells. An optimal...
5.
Yeh C, Wang S, Tsai C, Chen Y, Liu C, Chiang K, et al.
Int J Surg
. 2017 Jan;
39:30-36.
PMID: 28110026
Background: For selected patients with metastatic gastrointestinal stromal tumor (GIST) who have received first-line imatinib (IM) and are undergoing cytoreductive surgery, response to IM at time of surgery correlates with...
6.
Cheng C, Chu Y, Yeh C, Huang S, Chen M, Wang S, et al.
Onco Targets Ther
. 2015 Aug;
8:1899-907.
PMID: 26251613
Background And Objectives: Cholangiocarcinoma (CCA) affects thousands worldwide with increasing incidence. SPARC (secreted protein acidic and rich in cysteine) plays an important role in cellular matrix interactions, wound repair, and...
7.
Chen Y, Yeh C, Cheng C, Wu C, Chiang K, Chen T, et al.
Transl Oncol
. 2014 Nov;
7(5):620-5.
PMID: 25389456
Aim: Sunitinib has shown benefit in patients with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). However, its advantages are somewhat diminished because of associated toxicities. Herein, we clarify the efficacy and...
8.
Cheng C, Tsai C, Yeh C, Chiang K, Chen Y, Wang S, et al.
Anticancer Res
. 2014 Nov;
34(11):6617-25.
PMID: 25368266
Aim: Imatinib mesylate (IM) has substantial efficacy in patients with metastatic gastrointestinal stromal tumors (GISTs), and pathological complete response (pCR) following IM treatment has been sporadically reported; however, its clinical...
9.
Hsu C, Wu C, Chen J, Tseng J, Chiang K, Liu Y, et al.
Anticancer Res
. 2014 Sep;
34(9):5029-36.
PMID: 25202087
Aim: Imatinib mesylate (IM) is effective in metastatic gastrointestinal stromal tumor (GIST) patients; however, disease progression eventually occurs due to IM resistance or intolerance. Treatment options include IM escalation or...
10.
Yeh C, Chung W, Su S, Chen Y, Cheng C, Lin Y, et al.
J Invest Dermatol
. 2014 May;
134(11):2768-2775.
PMID: 24802849
Sunitinib, a multitargeted receptor Y kinase inhibitor (TKI) used for the treatment of renal cell carcinoma and gastrointestinal stromal tumor (GIST), is notorious for cutaneous adverse effects, such as hand-foot...